Compare USNA & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | ARCT |
|---|---|---|
| Founded | 1992 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 163.4M |
| IPO Year | 1996 | 2019 |
| Metric | USNA | ARCT |
|---|---|---|
| Price | $14.54 | $13.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 169.8K | ★ 952.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,060,902,000.00 | $82,031,000.00 |
| Revenue This Year | $3.90 | N/A |
| Revenue Next Year | $6.21 | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.57 | $5.50 |
| 52 Week High | $28.52 | $24.14 |
| Indicator | USNA | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 50.49 |
| Support Level | $12.57 | $13.12 |
| Resistance Level | $15.75 | $17.85 |
| Average True Range (ATR) | 0.52 | 1.28 |
| MACD | 0.11 | -0.50 |
| Stochastic Oscillator | 33.14 | 15.91 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.